151 related articles for article (PubMed ID: 10027647)
1. Immune globulin versus antivirals versus combination for prevention of cytomegalovirus disease in transplant recipients.
King SM
Antiviral Res; 1999 Jan; 40(3):115-37. PubMed ID: 10027647
[No Abstract] [Full Text] [Related]
2. Prophylactic antiviral therapy in CMV high-risk liver transplant recipients.
Rabkin JM; Rosen HR; Corless CL; Orloff SL; Olyaei AJ
Transplant Proc; 2001; 33(1-2):1811-2. PubMed ID: 11267523
[No Abstract] [Full Text] [Related]
3. Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study.
Snydman DR; Falagas ME; Avery R; Perlino C; Ruthazer R; Freeman R; Rohrer R; Fairchild R; O'Rourke E; Hibberd P; Werner BG
Transplant Proc; 2001 Jun; 33(4):2571-5. PubMed ID: 11406251
[No Abstract] [Full Text] [Related]
4. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
[TBL] [Abstract][Full Text] [Related]
5. Prevention of cytomegalovirus disease in transplant recipients.
Winston DJ
Lancet; 1995 Nov; 346(8987):1380-1. PubMed ID: 7475816
[No Abstract] [Full Text] [Related]
6. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients.
Bonaros NE; Kocher A; Dunkler D; Grimm M; Zuckermann A; Ankersmit J; Ehrlich M; Wolner E; Laufer G
Transplantation; 2004 Mar; 77(6):890-7. PubMed ID: 15077033
[TBL] [Abstract][Full Text] [Related]
7. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation.
Dunn DL; Gillingham KJ; Kramer MA; Schmidt WJ; Erice A; Balfour HH; Gores PF; Gruessner RW; Matas AJ; Payne WD
Transplantation; 1994 Mar; 57(6):876-84. PubMed ID: 8154035
[TBL] [Abstract][Full Text] [Related]
8. Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants.
Bailey TC; Ettinger NA; Storch GA; Trulock EP; Hanto DW; Dunagan WC; Jendrisak MD; McCullough CS; Kenzora JL; Powderly WG
Am J Med; 1993 Sep; 95(3):273-8. PubMed ID: 8396320
[TBL] [Abstract][Full Text] [Related]
9. [Cytomegalovirus infection in transplant recipients].
Gondo H
Nihon Rinsho; 1998 Jan; 56(1):173-8. PubMed ID: 9465685
[TBL] [Abstract][Full Text] [Related]
10. Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients.
Dickinson BI; Gora-Harper ML; McCraney SA; Gosland M
Ann Pharmacother; 1996 Dec; 30(12):1452-64. PubMed ID: 8968459
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus prophylaxis in solid organ transplant recipients.
Patel R; Snydman DR; Rubin RH; Ho M; Pescovitz M; Martin M; Paya CV
Transplantation; 1996 May; 61(9):1279-89. PubMed ID: 8629285
[No Abstract] [Full Text] [Related]
12. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients.
Singh N
Clin Infect Dis; 2001 Mar; 32(5):742-51. PubMed ID: 11229841
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus prophylaxis with ganciclovir, acyclovir, and CMV hyperimmune globulin in liver transplant patients receiving OKT3 induction.
Ham JM; Shelden SL; Godkin RR; Posner MP; Fisher RA
Transplant Proc; 1995 Oct; 27(5 Suppl 1):31-3. PubMed ID: 7482814
[No Abstract] [Full Text] [Related]
14. Successful treatment of severe cytomegalovirus infections with ganciclovir and CMV hyperimmune globulin in liver transplant recipients.
D'Alessandro AM; Pirsch JD; Stratta RJ; Sollinger HW; Kalayoglu M; Belzer FO
Transplant Proc; 1989 Jun; 21(3):3560-1. PubMed ID: 2545018
[No Abstract] [Full Text] [Related]
15. Preemptive versus prophylactic approaches in the management of cytomegalovirus disease in solid organ transplant recipients: what we know and what we do not know.
Meylan PR; Pascual M
Clin Infect Dis; 2006 Oct; 43(7):881-3. PubMed ID: 16941369
[No Abstract] [Full Text] [Related]
16. Prophylaxis and treatment of cytomegalovirus disease in recipients of solid organ transplants: current approach and future challenges.
Puius YA; Snydman DR
Curr Opin Infect Dis; 2007 Aug; 20(4):419-24. PubMed ID: 17609603
[TBL] [Abstract][Full Text] [Related]
17. Prophylaxis and treatment of CMV infections in transplantation.
Zaia JA
Adv Exp Med Biol; 1996; 394():117-34. PubMed ID: 8815679
[No Abstract] [Full Text] [Related]
18. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.
Fleming JN; Taber DJ; Weimert NA; Nadig S; McGillicuddy JW; Bratton CF; Baliga PK; Chavin KD
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921781
[TBL] [Abstract][Full Text] [Related]
19. Elimination of cytomegalovirus disease in liver transplant patients treated prophylactically with combination cytomegalovirus hyperimmune globulin and ganciclovir.
Prian GW; Koep LJ
Transplant Proc; 1994 Oct; 26(5 Suppl 1):54-5. PubMed ID: 7940977
[No Abstract] [Full Text] [Related]
20. Prevention of cytomegalovirus disease in transplant recipients.
Snydman DR; Falagas ME
Lancet; 1996 Jan; 347(8996):268-9. PubMed ID: 8551918
[No Abstract] [Full Text] [Related]
[Next] [New Search]
